By Wayne Koberstein, Executive Editor, Life Science Leader magazine
Follow Me On Twitter @WayneKoberstein
Developing small molecule drugs for rare neurodegenerative diseases
Nido Biosciences is in early clinical and preclinical development of small molecule drugs targeting neurodegenerative disorders with a variety of disease mechanisms. Its lead pipeline drug, coded NIDO-361, is in a Phase 1 trial for treatment of spinal and bulbar muscular atrophy (SBMA). Additional preclinical drug candidates will aim at ALS (amyotrophic lateral sclerosis), rare tauopathies, frontotemporal dementia (FTD), and other indications.